The pricing of the public offering by Intra-Cellular Therapies is a significant financial move, aiming to raise substantial capital. While the influx of funds is positive, the dilution of existing shares might temper short-term stock price appreciation. The net impact on the stock price could be neutral in the short term as the market balances the benefits of capital increase against the dilutive effect of the new shares.